Track market-moving stories before they get noisy

Shares of UnitedHealth Group jumped to their highest level in more than a year Thursday after the health care and insurance giant announced results that handily topped Wall Street expectations.

The condition is characterized by the presence of high levels of cholesterol in the blood, particularly “bad” LDL cholesterol.

The company said the treatment is the first FDA-approved oral PCSK9 inhibitor and is designed as a once-daily pill to lower LDL cholesterol.

According to the company, the approval was supported by positive results from two pivotal Phase 3 studies in its CORALreef clinical program.

Phase 3 Trials Show Significant LDL-C ReductionsThe FDA approval was based on findings from the Phase 3 CORALreef Lipids and CORALreef HeFH trials.

In the CORALreef Lipids study, patients receiving LIPFENDRA achieved a 56% reduction in LDL-C compared with placebo at week 24.

Under revised post-hoc data handling rules that excluded biologically impossible baseline LDL-C values, the reduction increased to 60%, while placebo patients recorded a 3% increase from baseline.

The trial also showed statistically significant reductions in other lipid measures associated with atherosclerotic cardiovascular disease risk. Non-high-density lipoprotein cholesterol fell by 54%, while apolipoprotein B declined by 50%.

CORALreef HeFH Results Support ApprovalIn the CORALreef HeFH trial involving adults with heterozygous familial hypercholesterolemia, LIPFENDRA reduced LDL-C by 59% compared with placebo at week 24.

From baseline, LDL-C declined by 58% in the treatment group, while placebo participants saw a 3% increase.

The study also reported a 52% reduction in non-HDL cholesterol and a 48% decline in apolipoprotein B compared with placebo.

Merck said an ongoing clinical trial is evaluating whether LIPFENDRA can reduce cardiovascular morbidity and mortality. The company noted that it has not yet been established whether the treatment lowers the risk of cardiovascular events or death.

MRK Price Action: Merck & Co shares were up 3.61% at $128.07 at the time of publication on Thursday. The stock is trading near its 52-week high of $130.29, according to Benzinga Pro data.

Image via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

, /PRNewswire/ -- The Goodyear Tire & Rubber Company (NASDAQ: GT) will report second quarter 2026 financial results after market close on Wednesday, August 5, followed by a conference call at 8:30 a.m. Eastern time on Thursday, August 6.

The Company will publish its results on August 5, in the form of an Earnings Release and an additional presentation on its investor website: http://investor.goodyear.com. The following morning, the Company will host a conference call.

The call can be accessed on the website or via telephone by calling either (833) 419-0865 or (785) 838-9333 before 8:25 a.m. and providing the conference ID "Goodyear." A replay will be available by calling (800) 723-1517 or (402) 220-2659. The replay will also be available on the website.

About The Goodyear Tire & Rubber Company
Goodyear is one of the world's largest tire companies. It employs about 63,000 people and manufactures its products in 49 facilities in 19 countries around the world. Its two Innovation Centers in Akron, Ohio, and Colmar-Berg, Luxembourg, strive to develop state-of-the-art products and services that set the technology and performance standard for the industry. For more information about Goodyear and its products, go to www.goodyear.com/corporate.

MEDIA CONTACT:
KELLY MCGLUMPHY
[email protected] 

ANALYST CONTACT:
RYAN REED
[email protected] 

SOURCE The Goodyear Tire & Rubber Company

-

SAN FRANCISCO--(BUSINESS WIRE)--Lyft, Inc. (Nasdaq: LYFT) (the “Company” or “Lyft”) will release financial results for the second quarter of 2026 after the close of the market on Thursday, August 6, 2026.

On the same day, Lyft will host a conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss these financial results and business highlights. To listen to the live audio webcast, please visit the Company’s Investor Relations page at https://investor.lyft.com.

The archived webcast will be available on the Company’s Investor Relations page shortly after the call.

Lyft announces material information to the public about the Company, its products and services and other matters through a variety of means, including filings with the Securities and Exchange Commission, press releases, public conference calls, webcasts, the investor relations section of its website (investor.lyft.com), its X accounts (including: @lyft, @davidrisher), its Chief Executive Officer’s LinkedIn account (linkedin.com/in/jdavidrisher), and its blogs (including: lyft.com/blog, lyft.com/hub, and eng.lyft.com) in order to achieve broad, non-exclusionary distribution of information to the public and to comply with its disclosure obligations under Regulation FD.

About Lyft

Whether it’s an everyday commute or a journey that changes everything, Lyft is driven by our purpose: to serve and connect. Founded in 2012, Lyft has grown into a global mobility platform offering a mix of rideshare, taxis, private hire vehicles, executive chauffeur services, car sharing, bikes, and scooters across six continents and thousands of cities. Millions of drivers have chosen to earn on billions of rides - helping to create a more connected world, with transportation options for everyone.

More News From Lyft, Inc.

Back to Newsroom

Spot gold weekly chart shows long-term trend. Source: TradingView Next Support Zones Come into Focus Now that gold has been rejected once again from resistance at the 20-day moving average, the developing bearish trend may be ready to proceed with its next leg lower. That would suggest that the prior trend low of $3,942 may be broken on the way to a test of support near the higher swing low of $3,886 from October 2025. There is also a reasonable chance that support may fail to hold near that low, which would provide another bearish reversal signal following the prior upswing.

A decisive decline below $3,886 would likely lead to the next lower target zone from approximately $3,704 to around $3,650, derived from the 50% retracement of a prior upswing and the 78.6% Fibonacci retracement of a smaller upswing that is contained within the larger trend structure. There may also be a test of the lower boundary of a falling trend channel near that price zone, depending on when it is reached. Signs of support may emerge near that lower boundary.

Longer-Term Trend Weakness Remains Intact Gold has been progressively weakening overall since the January peak of $5,597. The deterioration in the technical picture began to have longer-term implications in early June when a confirmed breakdown below an uptrend line and the 200-day moving average occurred. Resistance during bounces shifted from the 50-day moving average to the 20-day moving average, reflecting increasing bearish momentum. Three weeks ago, a longer-term uptrend line defining dynamic support was broken to the downside and the area near the line has been confirmed as resistance. Taken together, short-term weakness is now aligned with longer-term weakness, suggesting further downside and reinforcing the bearish outlook.

If you’d like to know more about how to trade gold and silver, please visit our educational area.

SUNNYVALE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended June 30, 2026.

Q2 Highlights

Worldwide procedures (da Vinci and Ion combined) grew approximately 16% compared with the second quarter of 2025. Da Vinci procedures grew approximately 15%, and Ion procedures grew approximately 36%.The Company placed 468 da Vinci surgical systems, compared with 395 in the second quarter of 2025. The second quarter 2026 da Vinci surgical system placements included 246 da Vinci 5 systems, compared with 180 in the second quarter of 2025. The Company placed 55 Ion endoluminal systems, compared with 54 in the second quarter of 2025.The Company grew its da Vinci surgical system installed base to 11,710 systems as of June 30, 2026, an increase of 12% compared with 10,488 as of June 30, 2025. The Company grew its Ion endoluminal system installed base to 1,096 systems as of June 30, 2026, an increase of 21% compared with 905 as of June 30, 2025.Second quarter 2026 revenue of $2.89 billion increased 19%, compared with $2.44 billion in the second quarter of 2025.Second quarter 2026 GAAP net income attributable to Intuitive Surgical, Inc. was $818 million, or $2.29 per diluted share, compared with $658 million, or $1.81 per diluted share, in the second quarter of 2025.Second quarter 2026 non-GAAP* net income attributable to Intuitive Surgical, Inc. was $1.00 billion, or $2.80 per diluted share, compared with $0.80 billion, or $2.19 per diluted share, in the second quarter of 2025.Second quarter 2026 GAAP and non-GAAP* net income attributable to Intuitive Surgical, Inc. included a benefit of $28 million, net of tax, or $0.08 per diluted share, related to refunds for tariffs paid in prior periods under the International Emergency Economic Powers Act (“IEEPA”).The Company repurchased 0.9 million shares of its common stock for $0.38 billion in the second quarter of 2026. Q2 Financial Summary

Gross profit, income from operations, net income attributable to Intuitive Surgical, Inc., and net income per diluted share attributable to Intuitive Surgical, Inc. are reported on a GAAP and non-GAAP* basis. The non-GAAP* measures are described below and are reconciled to the corresponding GAAP measures at the end of this release.

Second quarter 2026 revenue was $2.89 billion, an increase of 19% compared with $2.44 billion in the second quarter of 2025. The higher second quarter revenue was driven by growth in procedure volume, higher da Vinci system leasing revenue, and an increase in the installed base of da Vinci and Ion systems.

Second quarter 2026 instruments and accessories revenue increased by 18% to $1.73 billion, compared with $1.47 billion in the second quarter of 2025. The increase in instruments and accessories revenue was primarily driven by approximately 15% growth in da Vinci procedure volume and approximately 36% growth in Ion procedure volume.

Second quarter 2026 systems revenue was $685 million, compared with $575 million in the second quarter of 2025. The higher systems revenue reflected a higher lease installed base, higher da Vinci system average selling prices, and increased da Vinci system placements compared with the second quarter of 2025. The Company placed 468 da Vinci surgical systems, of which 246 were da Vinci 5 systems, in the second quarter of 2026, compared with 395 systems, of which 180 were da Vinci 5 systems, in the second quarter of 2025. The second quarter 2026 da Vinci surgical system placements included 254 systems placed under operating lease arrangements, of which 131 systems were placed under usage-based operating lease arrangements, compared with 193 systems placed under operating lease arrangements, of which 124 systems were placed under usage-based operating lease arrangements in the second quarter of 2025.

Second quarter 2026 GAAP income from operations increased to $972 million, compared with $743 million in the second quarter of 2025. Second quarter 2026 GAAP income from operations included share-based compensation expense of $213 million, compared with $200 million in the second quarter of 2025. Second quarter 2026 non-GAAP* income from operations increased to $1.22 billion, compared with $0.95 billion in the second quarter of 2025.

Second quarter 2026 GAAP net income attributable to Intuitive Surgical, Inc. was $818 million, or $2.29 per diluted share, compared with $658 million, or $1.81 per diluted share, in the second quarter of 2025. Second quarter 2026 GAAP net income attributable to Intuitive Surgical, Inc. included excess tax benefits of $17 million, or $0.05 per diluted share, compared with $33 million, or $0.09 per diluted share, in the second quarter of 2025. Additionally, second quarter 2026 GAAP net income included a benefit of $28 million, net of tax, or $0.08 per diluted share, related to refunds for tariffs paid in prior periods under IEEPA.

Second quarter 2026 non-GAAP* net income attributable to Intuitive Surgical, Inc. was $1.00 billion, or $2.80 per diluted share, compared with $0.80 billion, or $2.19 per diluted share, in the second quarter of 2025. Second quarter 2026 non-GAAP* net income included a benefit of $28 million, net of tax, or $0.08 per diluted share, related to refunds for tariffs paid in prior periods under IEEPA.

The Company ended the second quarter of 2026 with $8.63 billion in cash, cash equivalents, and investments, an increase of $0.65 billion during the quarter, primarily driven by cash generated from operations, partially offset by cash used for repurchases of common stock.

“We are pleased with company performance this quarter, which reflects the strength of our portfolio – from da Vinci and Ion to our growing digital solutions,” said Dave Rosa, Intuitive CEO. “Our commitment to customers around the world – our north star – remains the same: helping them deliver better patient outcomes, better patient and care team experiences, lower costs, and broader access to minimally invasive care.”

2026 Financial Outlook

The Company expects the following results for the full year of 2026:

Worldwide da Vinci procedure growth of approximately 13.5% to 15.5% in 2026. The Company expects to be closer to the midpoint of this range.Non-GAAP* gross profit margin to be within a range of 68.0% to 69.0% of revenue in 2026. This range includes an estimated impact from tariffs of 1.0% of revenue.Non-GAAP* operating expense growth of 11% to 13% in 2026. The range for expected non-GAAP* gross profit margin reflects the Company’s estimates of the adverse impact from tariffs that are currently in effect as of the time of this press release and assumes such tariffs remain in place through the end of the year. Should additional tariffs beyond our expectations be implemented, the additional impact on the Company’s financial results in 2026, including the change in expected non-GAAP* gross profit margin, could be material. The ultimate effect of tariffs will depend on various factors, including the proportion of components procured and finished goods manufactured outside of the United States and the amount, scope, nature, and timing of the tariffs.

The 2026 financial outlook provided above includes forward-looking, non-GAAP financial measures, which management uses in measuring performance. We do not provide a reconciliation of non-GAAP outlook measures to corresponding GAAP measures on a forward-looking basis, because we are unable to predict with reasonable certainty the exact timing and ultimate outcome of certain items, including but not limited to legal proceedings, without unreasonable efforts. These items are uncertain, depend on various factors, and could be material to the Company’s results computed in accordance with GAAP. For additional information regarding the nature of these items, refer to the reconciliations of historical GAAP to non-GAAP measures included elsewhere in this release.

Additional supplemental financial and procedure information has been posted to the Investor Relations section of the Intuitive website at https://isrg.gcs-web.com/.

Webcast and Conference Call Information

Intuitive will hold a teleconference at 1:30 p.m. PDT today to discuss the second quarter 2026 financial results. The call will be webcast live and can be accessed on Intuitive’s website at www.intuitive.com. For those individuals planning to participate on the call, registration can be completed online at https://edge.media-server.com/mmc/p/dekvotz4/ to receive dial-in details and an individual pin. The webcast replay of the call will be made available on our website at www.intuitive.com within 24 hours after the end of the live teleconference and will be accessible for at least 30 days.

About Intuitive

Intuitive (Nasdaq: ISRG), headquartered in Sunnyvale, California, is a global leader in minimally invasive care and the pioneer of robotic-assisted surgery. Our technologies include the da Vinci surgical systems and the Ion endoluminal system. By uniting advanced systems, progressive learning, and value-enhancing services, we help physicians and their teams optimize care delivery to support the best outcomes possible. At Intuitive, we envision a future of care that is less invasive and profoundly better, where diseases are identified early and treated quickly, so patients can get back to what matters most.

Product and brand names/logos are trademarks or registered trademarks of Intuitive or their respective owner. See www.intuitive.com/trademarks.

For more information, please visit the Company’s website at www.intuitive.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements relate to expectations concerning matters that are not historical facts. Statements using words such as “estimates,” “projects,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “may,” “will,” “could,” “should,” “commit,” “would,” “seek,” “potential,” “targeted,” and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements are necessarily estimates reflecting the judgment of the Company’s management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. These forward-looking statements include, but are not limited to the following: statements related to future results of operations, including expected procedure growth in 2026, expected non-GAAP gross profit margins in 2026, and expected non-GAAP operating expense growth in 2026; future financial position; the goals the Company shares with its customers, including improving patient outcomes; the estimated impact from tariffs, including the potential for material adverse impact on the Company’s financial results if additional tariffs beyond the Company’s current expectations are implemented; expectations regarding the continuation of share-based compensation expense as a significant recurring expense; the Company’s strategic vision for the future of minimally invasive care; and the Company’s inability to predict with reasonable certainty the exact timing and ultimate outcome of certain items, including legal proceedings. These forward-looking statements should be considered in light of various important factors, including, but not limited to, the following: the overall macroeconomic environment, which may impact customer spending and the Company’s costs, including tariffs, the levels of inflation, and interest rates; the conflict in Ukraine; conflicts in the Middle East, including Israel and Iran; disruption to the Company’s supply chain, including increased difficulties in obtaining a sufficient supply of materials; curtailed or delayed capital spending by hospitals; the impact of global and regional economic and credit market conditions on healthcare spending; delays in obtaining new product approvals, clearances, or certifications from the United States (“U.S.”) Food and Drug Administration (“FDA”), comparable regulatory authorities, or notified bodies; the risk of the Company’s inability to comply with complex FDA and other regulations, which may result in significant enforcement actions; regulatory approvals, clearances, certifications, and restrictions or any dispute that may occur with any regulatory body; healthcare reform legislation in the U.S. and its impact on hospital spending, reimbursement, and fees levied on certain medical device revenues; changes in hospital admissions and actions by payers to limit or manage surgical procedures; the timing and success of product development and customer acceptance of developed products; the results of any collaborations, in-licensing arrangements, joint ventures, strategic alliances, or partnerships, including the joint venture with Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; the Company’s completion of and ability to successfully integrate acquisitions, including the recently completed acquisition of the da Vinci and Ion distribution businesses in Italy, Spain, and Portugal and the transition from a distributor to a direct sales model in those markets; intellectual property positions and litigation; competition from companies offering alternative surgical approaches or robotic-assisted surgical systems, including domestic competitors in certain geographic markets such as China; risks associated with the Company’s operations and any expansion outside of the U.S.; unanticipated manufacturing disruptions or the inability to meet demand for products; the Company’s reliance on sole- and single-sourced suppliers; the results of legal proceedings to which the Company is or may become a party; adverse publicity regarding the Company and the safety of the Company’s products and adequacy of training; the impact of changes to tax legislation, guidance, and interpretations; changes in tariffs, trade barriers, and regulatory requirements (including changes to tariffs imposed by the U.S. on imports from various countries, including Mexico, where the Company currently manufactures a significant majority of its instruments and accessories, Germany, where the Company currently manufactures a majority of its endoscopes, and China, where the Company currently imports certain materials); hospital staffing constraints and labor availability; cybersecurity risks, including risks to the Company’s supply chain; and other risks and uncertainties. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release and which are based on current expectations and are subject to risks, uncertainties, and assumptions that are difficult to predict, including those risk factors identified under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as updated by the Company’s other filings with the Securities and Exchange Commission (“SEC”). The Company’s actual results may differ materially and adversely from those expressed in any forward-looking statement, and the Company undertakes no obligation to publicly update or release any revisions to these forward-looking statements, except as required by law.

*About Non-GAAP Financial Measures

To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles (“GAAP”), the Company uses the following non-GAAP financial measures: non-GAAP gross profit, non-GAAP income from operations, non-GAAP net income attributable to Intuitive, and non-GAAP net income per diluted share attributable to Intuitive (“EPS”). The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.

The Company uses these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. The Company believes that these non-GAAP financial measures provide meaningful supplemental information regarding its performance by excluding items such as amortization of intangible assets, share-based compensation (“SBC”) and long-term incentive plan (“LTIP”) expenses, acquisition-related items, gains on the sale of businesses and assets, and other special items. LTIP expense relates to phantom share awards granted in China by the Company’s Intuitive-Fosun joint venture to its employees that vest over four years and can remain outstanding for seven to ten years. These awards are valued based on certain key performance metrics. Accordingly, they are subject to significant volatility based on the performance of these metrics and are not tied to performance of the Company’s business within the period. The Company believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing its performance and when planning, forecasting, and analyzing future periods. These non-GAAP financial measures also facilitate management’s internal comparisons to its historical performance. The Company believes these non-GAAP financial measures are useful to investors, because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making, and (2) they are used by institutional investors and the analyst community to help them analyze the performance of the Company’s business.

Non-GAAP gross profit. The Company defines non-GAAP gross profit as gross profit, excluding SBC and LTIP expenses, amortization of intangible assets, and acquisition-related items.

Non-GAAP income from operations. The Company defines non-GAAP income from operations as income from operations, excluding SBC and LTIP expenses, amortization of intangible assets, a facilities asset abandonment charge, litigation charges, acquisition-related items, and gains on the sale of businesses and assets.

Non-GAAP net income attributable to Intuitive and EPS. The Company defines non-GAAP net income as net income attributable to Intuitive, excluding SBC and LTIP expenses, amortization of intangible assets, a facilities asset abandonment charge, litigation charges, acquisition-related items, gains on the sale of businesses and assets, gains or losses on strategic investments, tax adjustments, including the excess tax benefits associated with SBC arrangements and the net tax effects related to intra-entity transfers of non-inventory assets, and adjustments attributable to noncontrolling interest in joint venture, net of the related tax effects. The Company excludes the excess tax benefits associated with SBC arrangements as well as the tax effects associated with non-cash amortization of deferred tax assets related to intra-entity non-inventory transfers, because the Company does not believe these items correlate with the ongoing results of its core operations. The tax effects of the non-GAAP items are determined by applying a calculated non-GAAP effective tax rate, which is commonly referred to as the with-and-without method. Without excluding these tax effects, investors would only see the gross effect that these non-GAAP adjustments had on the Company’s operating results. The Company’s calculated non-GAAP effective tax rate is generally higher than its GAAP effective tax rate. The Company defines non-GAAP EPS as non-GAAP net income attributable to Intuitive divided by diluted shares outstanding, which are calculated as GAAP weighted-average outstanding shares plus dilutive potential shares outstanding during the period.

There are a number of limitations related to the use of non-GAAP measures versus measures calculated in accordance with GAAP. Non-GAAP gross profit, non-GAAP income from operations, non-GAAP net income attributable to Intuitive, and non-GAAP EPS exclude items such as SBC and LTIP expenses, amortization of intangible assets, excess tax benefits associated with SBC arrangements, and non-cash amortization of deferred tax assets related to intra-entity transfers of non-inventory assets, which are primarily recurring items. SBC expense has been, and will continue to be for the foreseeable future, a significant recurring expense in the Company’s business. In addition, the components of the costs that the Company excludes in its calculation of non-GAAP net income attributable to Intuitive and non-GAAP EPS may differ from the components that its peer companies exclude when they report their results of operations. Management addresses these limitations by providing specific information regarding the GAAP amounts excluded from non-GAAP net income attributable to Intuitive and non-GAAP EPS and evaluating non-GAAP net income attributable to Intuitive and non-GAAP EPS together with net income attributable to Intuitive and net income per share attributable to Intuitive calculated in accordance with GAAP.

 INTUITIVE SURGICAL, INC.
UNAUDITED QUARTERLY CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(IN MILLIONS, EXCEPT PER SHARE DATA)
  Three Months Ended June 30,
2026 March 31,
2026 June 30,
2025Revenue:     Instruments and accessories$1,734.9  $1,686.4  $1,474.1 Systems 685.0   650.7   574.7 Services 472.4   433.7   391.2 Total revenue 2,892.3   2,770.8   2,440.0 Cost of revenue:     Product 777.0   780.0   686.2 Service 154.9   160.3   135.9 Total cost of revenue (1) 931.9   940.3   822.1 Gross profit 1,960.4   1,830.5   1,617.9 Operating expenses:     Selling, general, and administrative 617.9   613.3   561.2 Research and development 370.6   361.9   313.3 Total operating expenses 988.5   975.2   874.5 Income from operations (2) 971.9   855.3   743.4 Interest and other income (expense), net 82.7   85.1   88.7 Income before taxes 1,054.6   940.4   832.1 Income tax expense (benefit) (3) 231.4   114.4   167.9 Net income 823.2   826.0   664.2 Less: net income attributable to noncontrolling interest in joint venture 5.1   4.5   5.8 Net income attributable to Intuitive Surgical, Inc.$818.1  $821.5  $658.4 Net income per share attributable to Intuitive Surgical, Inc.:     Basic$2.31  $2.31  $1.84 Diluted (4)$2.29  $2.28  $1.81 Weighted average shares outstanding:     Basic 354.1   354.9   358.5 Diluted 357.3   359.8   364.1       (1) Cost of revenue includes the following benefits related to refunds recognized for tariffs paid in prior periods under IEEPA:Product$27.5  $—  $— Service$8.4  $—  $— (2) Income from operations includes the effect of the following items:     Amortization of intangible assets$(24.0) $(7.1) $(3.2)Expensed IP charged to R&D$—  $—  $(1.6)(3) Income tax expense (benefit) includes the effect of the following items:     Excess tax benefits related to share-based compensation arrangements$(17.3) $(73.3) $(32.9)Discrete tax benefit from release of unrecognized tax benefits$—  $(1.6) $— (4) Diluted net income per share attributable to Intuitive Surgical, Inc. includes the effect of the following items:     IEEPA tariff refunds, net of tax$0.08  $—  $— Amortization of intangible assets, net of tax$(0.05) $(0.02) $(0.01)Expensed IP charged to R&D, net of tax$—  $—  $— Excess tax benefits related to share-based compensation arrangements$0.05  $0.20  $0.09 Discrete tax benefit from release of unrecognized tax benefits$—  $—  $—    INTUITIVE SURGICAL, INC.
UNAUDITED YEAR-TO-DATE CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(IN MILLIONS, EXCEPT PER SHARE DATA)   Six Months Ended June 30,  2026   2025 Revenue:   Instruments and accessories$3,421.3  $2,841.8 Systems 1,335.7   1,097.4 Services 906.1   754.2 Total revenue 5,663.1   4,693.4 Cost of revenue:   Product 1,557.0   1,356.9 Service 315.2   260.9 Total cost of revenue (1) 1,872.2   1,617.8 Gross profit 3,790.9   3,075.6 Operating expenses:   Selling, general, and administrative 1,231.2   1,124.6 Research and development 732.5   629.5 Total operating expenses 1,963.7   1,754.1 Income from operations (2) 1,827.2   1,321.5 Interest and other income, net 167.8   179.1 Income before taxes 1,995.0   1,500.6 Income tax expense (3) 345.8   132.7 Net income 1,649.2   1,367.9 Less: net income attributable to noncontrolling interest in joint venture 9.6   11.1 Net income attributable to Intuitive Surgical, Inc.$1,639.6  $1,356.8 Net income per share attributable to Intuitive Surgical, Inc.:   Basic$4.63  $3.79 Diluted (4)$4.57  $3.72 Weighted average shares outstanding:   Basic 354.5   358.0 Diluted 358.5   364.4     (1)Cost of revenue includes the following benefits related to refunds recognized for tariffs paid in prior periods under IEEPA:Product$27.5  $— Service$8.4  $— (2) Income from operations includes the effect of the following items:   Amortization of intangible assets$(31.1) $(6.6)Expensed IP charged to R&D$—  $(6.7)(3) Income tax expense includes the effect of the following items:   Excess tax benefits related to share-based compensation arrangements$(90.6) $(178.3)Discrete tax benefit from release of unrecognized tax benefits$(1.6) $(0.5)(4) Diluted net income per share attributable to Intuitive Surgical, Inc. includes the effect of the following items:IEEPA tariff refunds, net of tax$0.08  $— Amortization of intangible assets, net of tax$(0.06) $(0.01)Expensed IP charged to R&D, net of tax$—  $(0.01)Excess tax benefits related to share-based compensation arrangements$0.25  $0.49 Discrete tax benefit from release of unrecognized tax benefits$—  $—   INTUITIVE SURGICAL, INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(IN MILLIONS)
  June 30,
2026 December 31,
2025Cash, cash equivalents, and investments$8,625.5 $9,034.1Accounts receivable, net 1,673.2  1,527.3Inventory 2,028.7  1,840.0Property, plant, and equipment, net 5,551.5  5,342.4Goodwill 580.6  370.3Deferred tax assets 652.4  1,018.6Other assets 1,764.7  1,326.0Total assets$20,876.6 $20,458.7    Accounts payable and other liabilities$1,916.9 $1,918.9Deferred revenue 662.0  598.1Total liabilities 2,578.9  2,517.0Stockholders’ equity 18,297.7  17,941.7Total liabilities and stockholders’ equity$20,876.6 $20,458.7      INTUITIVE SURGICAL, INC.
UNAUDITED RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(IN MILLIONS, EXCEPT PER SHARE DATA)
       Three Months Ended Six Months Ended  June 30,
2026 March 31,
2026 June 30,
2025 June 30,
2026 June 30,
2025GAAP gross profit $1,960.4  $1,830.5  $1,617.9  $3,790.9  $3,075.6 GAAP gross profit margin (1)  67.8%  66.1%  66.3%  66.9%  65.5%Share-based compensation expense  36.2   36.0   36.6   72.2   72.8 Long-term incentive plan expense  (0.1)  0.1   0.1   —   0.4 Amortization of intangible assets  23.3   6.6   2.5   29.9   4.9 Acquisition-related items  4.1   5.9   —   10.0   — Non-GAAP gross profit $2,023.9  $1,879.1  $1,657.1  $3,903.0  $3,153.7 Non-GAAP gross profit margin (1)  70.0%  67.8%  67.9%  68.9%  67.2%           GAAP income from operations $971.9  $855.3  $743.4  $1,827.2  $1,321.5 Share-based compensation expense  209.9   209.5   196.2   419.4   381.4 Long-term incentive plan expense  (0.4)  0.5   0.3   0.1   1.1 Amortization of intangible assets  24.0   7.1   3.2   31.1   6.6 Facilities asset abandonment charge  6.9   —   —   6.9   — Litigation charges  —   6.3   3.5   6.3   3.5 Gains on sale of businesses and assets  —   (7.9)  —   (7.9)  — Acquisition-related items  5.7   6.0   —   11.7   — Non-GAAP income from operations $1,218.0  $1,076.8  $946.6  $2,294.8  $1,714.1            GAAP net income attributable to Intuitive Surgical, Inc. $818.1  $821.5  $658.4  $1,639.6  $1,356.8 Share-based compensation expense  209.9   209.5   196.2   419.4   381.4 Long-term incentive plan expense  (0.4)  0.5   0.3   0.1   1.1 Amortization of intangible assets  24.0   7.1   3.2   31.1   6.6 Facilities asset abandonment charge  6.9   —   —   6.9   — Litigation charges  —   6.3   3.5   6.3   3.5 Gains on sale of businesses and assets  —   (7.9)  —   (7.9)  — (Gains) losses on strategic investments  (0.2)  (0.6)  4.4   (0.8)  5.0 Acquisition-related items  5.7   6.0   —   11.7   — Tax adjustments (2)  (62.1)  (141.1)  (67.8)  (203.2)  (294.4)Adjustments attributable to noncontrolling interest in joint venture  0.2   (0.2)  (0.3)  —   (0.6)Non-GAAP net income attributable to Intuitive Surgical, Inc. $1,002.1  $901.1  $797.9  $1,903.2  $1,459.4            GAAP net income per share attributable to Intuitive Surgical, Inc. - diluted $2.29  $2.28  $1.81  $4.57  $3.72 Share-based compensation expense  0.59   0.58   0.54   1.17   1.05 Long-term incentive plan expense  —   —   —   —   — Amortization of intangible assets  0.07   0.02   0.01   0.09   0.02 Facilities asset abandonment charge  0.02   —   —   0.02   — Litigation charges  —   0.02   0.01   0.02   0.01 Gains on sale of businesses and assets  —   (0.02)  —   (0.02)  — (Gains) losses on strategic investments  —   —   0.01   —   0.01 Acquisition-related items  0.01   0.01   —   0.03   — Tax adjustments (2)  (0.18)  (0.39)  (0.19)  (0.57)  (0.81)Adjustments attributable to noncontrolling interest in joint venture  —   —   —   —   — Non-GAAP net income per share attributable to Intuitive Surgical, Inc. - diluted $2.80  $2.50  $2.19  $5.31  $4.00            (1) Gross profit margin is calculated by dividing gross profit by revenue. (2) For the three months ended June 30, 2026, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of $(17.3) million, or $(0.05) per diluted share; (b) the tax impact related to intra-entity transfers of non-inventory assets of $10.7 million, or $0.03 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of $(55.5) million, or $(0.16) per diluted share. For the three months ended June 30, 2025, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of $(32.9) million, or $(0.09) per diluted share; (b) the tax impact related to intra-entity transfers of non-inventory assets of $10.7 million, or $0.03 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of $(45.6) million, or $(0.13) per diluted share. For the six months ended June 30, 2026, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of $(90.6) million, or $(0.25) per diluted share; (b) tax impact related to intra-entity transfers of non-inventory assets of $21.4 million, or $0.06 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of $(134.0) million, or $(0.37) per diluted share. For the six months ended June 30, 2025, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of $(178.3) million, or $(0.49) per diluted share; (b) tax impact related to intra-entity transfers of non-inventory assets of $21.4 million, or $0.06 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of $(137.5) million, or $(0.38) per diluted share.
  Contact: Investor Relations
(408) 523-2161

Yanjun Wang, the CCO and GC of Sea Limited (SE 4.62%), sold 3,000 Class A ordinary shares in an indirect transaction on July 14 and July 15, 2026, according to an SEC Form 4 filing.

Transaction summaryMetricValueTransaction value$332,310Shares sold (indirectly held)3,000Post-transaction shares (directly held)1,162,442Post-transaction shares (indirectly held)34,000Post-transaction value$133.24 millionTransaction value based on SEC Form 4 weighted average sale price ($110.77); post-transaction value based on July 15, 2026 market close ($111.36).

Key questionsWhat was the mechanism for this share disposal?
The transaction was executed via a British Virgin Islands entity under a Rule 10b5-1 trading plan established in March 2026. These plans allow insiders to schedule transactions in advance to mitigate concerns regarding the possession of material non-public information.What is the current scale of the insider's equity alignment?
Following this sale, Wang maintains significant exposure to the company through about 1.2 million directly held shares and 34,000 shares held indirectly. This position indicates a high degree of ongoing alignment with shareholder interests.How does the current activity relate to total holdings?
The sale of 3,000 shares liquidated only 0.25% of the insider's total beneficial ownership. This modest reduction suggests the transaction is a routine portfolio management event rather than a shift in institutional conviction.What is the recent performance context for the security?
As of July 15, 2026, the transaction date, the company has generated a one-year total return of -30%, providing a clinical backdrop to this pre-scheduled liquidity event.Company OverviewMetricValueShare Price (as of market close 2026-07-15)$111.36Market Capitalization$68.2 billionRevenue (TTM)$25.2 billionNet Income (TTM)$1.6 billionCompany SnapshotSea Limited operates three core business segments: digital entertainment through its Garena platform offering online games and eSports events, e-commerce operations serving consumers across Southeast Asia and Latin America, and digital financial services providing payment and fintech solutions to its customer base.The company generates revenue through multiple channels, including in-game purchases and advertising within its digital entertainment platform, transaction fees and commissions from e-commerce marketplace operations, and service fees from its digital financial services offerings.Sea Limited primarily serves digital-native consumers and merchants across Southeast Asia, Latin America, and other emerging markets, with a particular focus on mobile-first users in developing economies seeking gaming entertainment, online shopping, and financial services.Sea Limited is a diversified digital platform operator with a $68.2 billion market capitalization and TTM revenues of $25.2 billion, positioning it as a leading technology conglomerate in emerging markets. The company leverages its integrated ecosystem spanning entertainment, commerce, and fintech to capture multiple revenue streams while maintaining significant scale across geographically fragmented markets. Sea's competitive advantage derives from its multi-platform approach, deep regional expertise in Southeast Asia and Latin America, and ability to cross-monetize its user base across its three core business segments.

What this transaction means for investorsThis sale ultimately looks like another scheduled slice off the same plan that Wang’s been using to sell off every few days over a period of months. Wang sold through a BVI entity, and it’s worth noting that 3,000 shares clears just a quarter of a percent of her stake while she keeps more than 1.2 million shares. When an insider sells small, regular amounts on autopilot, as is the case here, the recurring nature is itself the tell: this is programmed diversification, not someone reacting to the stock's rough year. If anything, the louder signal points the other way, since Sea has been buying back its own shares under a $1 billion program.

The business keeps outrunning its stock. Sea's first-quarter revenue jumped 47% to $7.1 billion, and adjusted EBITDA topped $1 billion for the first time, powered by Shopee's record volume and a fast-growing lending arm. CEO Forrest Li framed 2026 as a year to lean into growth while holding financial discipline. Ultimately, for long-term investors, this recurring selling is noise. More important will be whether Shopee's profitability holds and whether the firm’s expanding SME loan book, which climbed 71% to nearly $10 billion, stays clean.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Sea Limited. The Motley Fool has a disclosure policy.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Regeneron Therapeutics, Inc. (NASDAQ: REGN) from August 1, 2025 to May 15, 2026. Regeneron is a pharmaceutical company that discovers, invents, develops, manufactures, tests, and commercializes medicines to treat various disorders worldwide.

Robbins LLP is Investigating Allegations that Regeneron Therapeutics, Inc. (REGN) Misled Investors Regarding the Viability of its Phase III Fianlimab-Libtayo Study

ShareFor more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

The Allegations: Robbins LLP is Investigating Allegations that Regeneron Therapeutics, Inc. (REGN) Misled Investors Regarding the Viability of its Phase III Fianlimab-Libtayo Study

According to the complaint, during the relevant period, Regeneron was investigating Fianlimab, a human monoclonal antibody targeting the LAG-3 immune checkpoint receptor on T-cells. Fianlimab was pertinently being tested in combination with Libtayo in a phase 3 study to determine whether the drug combination could serve as a first-line treatment for advanced melanoma (the “Phase III Fianlimab-Libtayo Study”). The study had commenced enrollment in mid-2022.

Plaintiff alleges that defendants provided overwhelmingly positive statements to investors while, at the same time, concealing the true state of Regeneron’s Phase III Fianlimab Libtayo Study; notably, that (i) its preliminary statistical assumptions were fundamentally flawed; (ii) the active treatment arm was failing to achieve meaningful clinical differentiation over standard therapies; and (iii) the trial would ultimately fail to reach statistical significance on its primary endpoint even without overperformance of the control arm.

Plaintiff alleges that April 29, 2026, during Regeneron’s first quarter earnings call, defendants disclosed the Phase III Fianlimab-Libtayo Study had been altered, expanding the number of patients in the study eligible for “analysis of progression-free survival.” On this news, the price of Regeneron’s common stock declined from a closing market price of $731.77 per share on April 28, 2026, to $686.36 per share on April 29, 2026, a decline of about 6.2% in the span of just a single day. Then, after-market on May 15, 2026, Regeneron announced that the “Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS).” On this news, the price of Regeneron’s common stock declined from $698.25 per share on May 15, 2026, to $629.68 per share on May 18, 2026, a decline of about 9.8% in the span of one day.

What Now: You may be eligible to participate in the class action against Regeneron Therapeutics, Inc. Shareholders who wish to serve as lead plaintiff for the class should contact Robbins LLP. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, Robbins LLP has helped restore more than $1 billion in value to shareholders, secured some of the largest recoveries in shareholder derivative litigation history, and achieved governance reforms at over 400 Fortune 1000 companies.

"Behind everything we do is the belief that companies should be governed responsibly, fiduciaries should be held accountable, and shareholders deserve transparency and fairness," said Brian J. Robbins, Founding Partner of Robbins LLP.

To be notified if a class action against Regeneron Therapeutics, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

The world’s largest semiconductor foundry, Taiwan Semiconductor ((TSM - Free Report) ), delivered another exceptional quarterly earnings report this morning, reinforcing the strength and durability of the global AI investment cycle.

In US dollars, second quarter revenue was $40.20 billion, which increased 33.7% year-over-year and increased 12.0% from the previous quarter.Raised full-year 2026 revenue growth guidance to slightly above 40% in US dollar terms, up from its previous projection of 30%.Chips using advanced technologies (7-nanometer and below) accounted for 77% of wafer revenue.Alongside the financial news, TSMC announced an additional $100 billion investment plan for its Arizona fabrication plants, for a total of $265 billion.Altogether, this was a highly encouraging update on the business, with broad implications for the endurance of the AI boom. While investors have grown increasingly concerned about the scale of hyperscaler spending, and the rising use of debt to fund that investment, TSMC appears more than comfortable expanding capacity and moving closer to the source of demand.

As a critical piece of infrastructure supporting the AI buildout, TSM shares have compounded at an extraordinary annualized rate of 61.6% since the beginning of 2023, producing a total return of roughly 450%. Despite the strong report, the stock is down ~3% as of this writing.

Image Source: Zacks Investment Research

Should Investors Be Selling TSM Shares too?With TSM shares selling off following the earnings report, investors may be wondering whether they should follow the market’s lead. However, given the company’s central role in the AI buildout and broader semiconductor industry, the weakness is more likely a bout of profit-taking after a strong run, compounded by renewed skepticism and selling across the AI trade.

Taiwan Semiconductor’s outlook is undoubtedly tied to the continued expansion of the AI boom. Even so, its current growth forecasts remain compelling, particularly in the context of the stock’s valuation. Sales are expected to grow 32% this year and another 27% next year, while earnings are projected to rise 45% this year and 27.5% next year.

Despite that growth, TSM trades at roughly 27x forward earnings, giving the stock a PEG ratio near 1. With powerful thematic momentum behind the business and production capacity expanding in the United States, there may also be room for valuation multiple expansion on top of the expected earnings growth.

Furthermore, TSM carries a Zacks Rank #2 (Buy), reflecting positive earnings estimate momentum. Over the past 30 days, analysts have unanimously raised their estimates across the board, reinforcing the strength of the company’s near-term outlook.

Image Source: Zacks Investment Research

The AI Pendulum Swings Back Toward SkepticismThroughout the AI boom, investor sentiment has repeatedly swung between exuberance and skepticism. Strong advances encourage increasingly aggressive expectations, which eventually give way to concerns about overspending, competition and uncertain returns on investment. Those resets can produce sharp volatility even when the underlying growth cycle remains intact.

TSMC’s results suggest that the current weakness is still more of a sentiment and positioning correction than a deterioration in the fundamental AI thesis. The stock may need time to digest its gains, but accelerating revenue growth, rising estimates and another major capacity commitment indicate that demand remains strong.

That outlook would change if hyperscalers began materially reducing capital expenditures or if TSMC showed signs of excess capacity and weakening advanced-chip demand. For now, however, the pendulum appears to be swinging toward excessive pessimism even as the company’s operating performance continues to strengthen.

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has agreed to be acquired by Eli Lilly and Co (NYSE:LLY) in a transaction valued at up to approximately $3.8 billion, with the deal adding the clinical-stage biotechnology company's pipeline of investigational therapies for treatment-resistant depression and other mental health conditions to Lilly's neuroscience portfolio.

Under the terms of the agreement, Lilly will pay $6.75 per share in cash at closing, representing an aggregate equity value of about $2.8 billion.

Shareholders will also receive contingent value rights (CVRs) worth up to an additional $2.50 per share if specified clinical, regulatory and commercialization milestones for AtaiBeckley's lead programs are achieved, bringing the potential total equity value to about $3.8 billion.

The purchase price represents a premium of about 40% to AtaiBeckley's 30-day volume-weighted average share price, according to Lilly.

Lilly said the acquisition would strengthen its neuroscience portfolio by adding therapies designed to restore synaptic connectivity, an approach that differs from conventional antidepressants that primarily target neurotransmitter levels.

AtaiBeckley's lead candidate, BPL-003, is an intranasal synthetic form of 5-MeO-DMT being developed for treatment-resistant depression. The company said the therapy demonstrated rapid and durable reductions in depressive symptoms in a Phase 2b trial and has received Breakthrough Therapy Designation from the US Food and Drug Administration. Phase 3 activities have begun.

The company's second most advanced program, VLS-01, is a buccal film formulation of DMT that is currently being evaluated in a Phase 2b study.

"Treatment-resistant depression persists even after multiple treatments have failed. Millions of people are still searching for relief and desperately need a therapy that works," Carole Ho, executive vice president and president of Lilly Neuroscience, said in a statement.

"Advancing AtaiBeckley's investigational therapies gives us a real chance to change that."

AtaiBeckley CEO and co-founder Srinivas Rao said the transaction could accelerate development of the company's pipeline.

"Across our portfolio, we're seeking to demonstrate that psychiatric illness is treatable at its biological root, not just its symptoms," Rao said. "Lilly's expertise and reach are expected to accelerate that work for people whose conditions have not responded to existing treatments."

Christian Angermayer, founder, largest shareholder and chairman of AtaiBeckley, said the deal represented "the best path forward for patients and shareholders."

The transaction is expected to close in the third quarter of 2026, subject to approval by AtaiBeckley shareholders, regulatory approvals and other customary closing conditions.

Apeiron Investment Group and all AtaiBeckley directors and officers have entered voting and support agreements backing the transaction. The shares covered by those agreements represent approximately 15% of the company's outstanding common stock.

Goldman Sachs is serving as Lilly's exclusive financial adviser, while Moelis & Company and Centerview Partners are advising AtaiBeckley.

Shares of AtaiBeckley jumped over 33% at Thursday's open to sit around $7.15.

Sales of the Prologue, an electric SUV, will end this year amid a pivot to hybrids.

NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Roblox Corporation (NYSE: RBLX) between October 30, 2025 and April 30, 2026, inclusive (the “Class Period”), of the important August 7, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Roblox common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Roblox class action, go to https://rosenlegal.com/cases/roblox-corporation-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 7, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Roblox’s organic growth potential; notably, that Roblox would see a significant slowdown in its growth rates as enrollment in the age verification rollout would quickly taper, compounding the resulting slowdown in on-platform communication, resulting in app store rating reductions and a swift reduction in organic growth. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Roblox class action, go to https://rosenlegal.com/cases/roblox-corporation-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

The State Street SPDR S&P Aerospace & Defense ETF (XAR 2.73%) provides more affordable access to the defense and aircraft manufacturing industry, whereas the U.S. Global Jets ETF (JETS +0.00%) focuses specifically on global airline operators.

Investors looking to gain exposure to the aviation sector may find these two funds offer very different risk-return profiles. While one fund focuses on the cyclical nature of commercial travel, the other aligns with broader industrial manufacturing and national security spending.

Snapshot (cost & size)MetricJETSXARIssuerU.S. GlobalState StreetShare price$31.25 (as of 2026-07-15)$266.32 (as of 2026-07-15)Expense ratio0.60%0.35%1-yr return (as of 2026-07-15)27.20%24.50%Dividend yield0.70%0.30%Beta1.181.00AUM$851.4 million$6.0 billionBeta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-year return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.

The State Street fund is the more affordable option, with an expense ratio of 0.35% compared to the 0.60% charged by the U.S. Global fund. In terms of income, the U.S. Global ETF provides a higher trailing distribution payout.

Performance & risk comparisonMetricJETSXARMax drawdown (5 yr)(40.40%)(28.30%)Growth of $1,000 over 5 years (total return)$1,415$2,190What's insideThe State Street SPDR S&P Aerospace & Defense ETF focuses on industrials at 98% and technology at 2%. It holds 47 positions, and its largest positions include Axon Enterprise (AXON +0.05%) at 3.35%, VSE (VSEC 3.03%) at 3.30%, and Hexcel (HXL 1.01%) at 3.05%. The fund was launched in 2011. The State Street SPDR S&P Aerospace & Defense ETF has paid $0.81 per share over the trailing 12 months, which on its recent ~$266.32 share price works out to a 0.30% yield.

The U.S. Global Jets ETF targets industrials at 89%, consumer cyclical at 8%, and technology at 3%. It holds 45 positions, and its top holdings include Southwest Airlines (LUV +0.40%) at 10.61%, American Airlines Group (AAL 0.19%) at 10.57%, and United Airlines (UAL 1.79%) at 10.56%. The fund was launched in 2015. The U.S. Global Jets ETF has paid $0.23 per share over the trailing 12 months, which on its recent ~$31.25 share price works out to a 0.70% yield.

For more guidance on ETF investing, check out the full guide at this link.

What this means for investorsFor investors seeking exposure to the aviation industry, the State Street SPDR S&P Aerospace & Defense ETF (XAR) and U.S. Global Jets ETF (JETS) provide an efficient way to do so. Which to choose depends on whether you prefer XAR’s equal-weight approach to the aerospace and defense sector, or JETS’ focus on airlines using a tiered weighting methodology.

JETS represents a pure-play bet on the travel industry and commercial aviation. The fund allocates its portfolio holdings into tiers with the top four U.S. airlines each receiving 10% weighting, giving them an outsized impact on the ETF’s performance. The travel sector is on the upswing from pandemic-era struggles, making JETS a compelling fund to capture this growth, although its expense ratio is high and it’s more volatile than XAR, as illustrated by its higher beta and five-year max drawdown.

XAR provides exposure to the defense sector, which has seen increased federal spending under the Trump Administration. Its equal weighting ensures larger companies don’t dominate fund performance, which takes advantage of the higher growth potential of the smaller businesses among its holdings. XAR is the fund for investors who want to take advantage of the “Security Supercycle” driven by escalating geopolitical tensions and heavy government investment in military readiness and modernization.

China’s XPeng XPEV unveiled its new L03 sport-utility vehicle in Munich, marking the company’s first global vehicle launch outside China as it steps up expansion in Europe and other overseas markets amid intensifying competition at home.

The L03 model has a starting price of 35,600 euros, equivalent to about $40,800, in Germany for the battery-electric version, while the extended-range model starts at €38,600. In China, prices range from 123,800 yuan to 156,800 yuan, equivalent to around $18,300 to $23,045.

Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Videos

Further Reading

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Pentair plc (“Pentair” or the “Company”) (NYSE: PNR) investors concerning the Company's possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON PENTAIR PLC (PNR), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.What Happened?On July 15, 2026, Pentair.

Cintas Corporation (NASDAQ:CTAS) was upgraded to ‘Buy’ from Neutral by Bank of America, which also raised its price objective to $230 from $200 after the company's better-than-expected fourth-quarter fiscal 2026 results and fiscal 2027 guidance came in above Wall Street expectations.

The analysts wrote that they are "incrementally more constructive on the setup for earnings over the next several quarters" as Cintas benefits from improving labor market conditions in key industries, continued growth in adjacent product categories, and margin expansion driven by supply chain and distribution initiatives.

Bank of America expects Cintas to deliver another year of high-single-digit revenue growth alongside stronger margins. The firm highlighted technology investments, including SmartTruck, automated sorting, garment sharing and robotics, noting these initiatives have contributed more than 400 basis points of margin expansion over the past five years.

The analysts also pointed to improving employment trends in Cintas' core customer markets, which they believe should support customer additions and stronger revenue growth.

They added that the company's First Aid and Fire Safety businesses continue to benefit from cross-selling opportunities through its recurring route-based model.

Bank of America also identified Cintas' proposed acquisition of UniFirst as a potential catalyst. While the transaction remains under a second request from the US Federal Trade Commission, the analysts wrote they remain constructive on the deal's strategic rationale and believe the estimated $375 million in synergies "could be conservative."

The firm raised its valuation multiple to 39 times earnings from 37 times, reflecting greater confidence in potential earnings upside. While this represents a premium to business services peers, Bank of America wrote the valuation is supported by Cintas' consistent high-single-digit growth profile, cross-selling momentum and technology-driven productivity improvements.

Shares of Cintas traded higher on the upgrade, up 7% at $206.

, /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Lucid Group, Inc. ("Lucid" or the "Company") (NASDAQ: LCID).

IF YOU SUFFERED A LOSS ON YOUR LUCID INVESTMENTS, CLICK HERE BEFORE JULY 28, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT

What Is The Lawsuit About? 
The complaint filed alleges that, between February 25, 2026 and April 13, 2026, Defendants failed to disclose to investors that: (1) a supplier quality issue had significantly disrupted deliveries of the Lucid Gravity; (2) the foregoing was likely to, and did, have a material negative impact on the Company's business and financial results; (3) accordingly, the Defendants had overstated the purported enhancements to Lucid's manufacturing and delivery capabilities and overall operations; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More: 
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email:  [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

If you inquire by email, please include your mailing address, telephone number and number of shares purchased.  

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us: 
Glancy Prongay Wolke & Rotter LLP,  
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Charles Linehan
Email:  [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.

SOURCE Glancy Prongay Wolke & Rotter LLP

Dell Technologies (DELL) has emerged as one of the biggest beneficiaries of the AI infrastructure boom, with record demand for its AI-optimized servers driving explosive revenue and earnings growth. In this Tech Corner, George Tsilis breaks down Dell's expanding AI server backlog, partnership with Nvidia, and why enterprises and governments are increasingly turning to Dell for next-generation data center infrastructure.

Corrections, or declines of 10% to 20% from recent highs, are normal and can occur for a variety of reasons. To the latter point, investors considering individual stocks need to assess why a particular name is in the correction "penalty box."

Inevitably, some corrections signal more bearishness to come, but there are examples of stocks pulling back from their 52-week highs, offering investors potentially compelling opportunities to get involved. Snack giant Mondelez (MDLZ +4.60%) is in the latter category.

Shares of the Ritz maker, which yield 3.3%, reside 17.4% below the 52-week high as of Tuesday, July 14. That's close to a bear market (a decline of 20% or more), but there are reasons to believe this consumer staples stock can get its groove back.

Mondelez is a dividend stock to consider buying on the dip. Image source: Getty Images.

The Fed and a cocoa conundrum If there's a bright side to the pullback experienced by Mondelez stock since notching its 52-week high, it's that the culprits are easy to understand. The big offenders are the Federal Reserve and high cocoa prices. Mondelez isn't a dedicated chocolate company, but it makes Cadbury chocolate products and Oreos, making it a major cocoa buyer.

Unfortunately, the price of that commodity is soaring, and when that happens, Mondelez passes its higher input costs on to already inflation-wary consumers. Inflation is involved in how the Fed affects high-dividend stocks like Mondelez. Rate hikes are the "blunt instruments" typically deployed by central banks to dampen high consumer and producer prices.

Often, that's problematic for high-dividend stocks. Higher interest rates usually push Treasury yields higher, prompting many income investors to favor lower-risk U.S. government debt over dividend stocks.

The June reading of the Consumer Price Index (CPI) released Tuesday fell 0.4%, the largest monthly drop since April 2020. There's still work to be done on the inflation front, but in what could be good news for Mondelez, Fed funds futures show a high probability the central bank will stand pat at its meeting later this month. Standing pat is better than a rate hike.

Today's Change

(

4.60

%) $

2.70

Current Price

$

61.42

Here's something else that shouldn't be overlooked regarding Mondelez: Although the stock trades well below its 52-week high, it's up year to date. Actually, it's outperforming the S&P 500 and the broader consumer staples sector, indicating that even with the cocoa and Fed headwinds, the stock has been surprisingly durable.

A healthy, tasty dividend Yes, high bond yields can be a drag on select dividend stocks, particularly those from defensive sectors, which Mondelez certainly is. However, there's something for long-term equity income investors to consider with this stock.

Not only has Mondelez boosted its payout for 14 consecutive years, but some experts see the dividend rising in the high single digits annually through 2035. It's an attainable target, particularly since the company has no debt coming due for another five years.

For the sake of argument, let's say "high-single-digit" payout growth equals 7% and core inflation remains stuck at 2.6%, as was the case last month. There are no guarantees that those scenarios will play out in unison, but the point is that Mondelez has the potential to deliver inflation-thumping dividend growth over the long term.

Key Takeaways Western Digital expects stronger Q4 FY2026 revenues and higher margins on robust AI storage demand. Seagate projects higher Q4 FY2026 revenues, backed by growing data-center storage demand and cash flow.Western Digital and Seagate project strong earnings growth as AI storage demand remains robust. The boom in artificial intelligence (AI) has led to persistent demand for NVIDIA Corporation’s (NVDA - Free Report) state-of-the-art AI hardware, including graphics processing units and Blackwell chips. That demand propelled NVIDIA to become the world’s most valuable company, with a market capitalization of over $4 trillion, and its stock has delivered strong returns over the past few years.  

However, NVIDIA’s growth has led to the company trading at a premium in comparison to most of the other semiconductor players, leaving little room for disappointment if growth derails. A slowdown in AI infrastructure spending by hyperscale cloud providers could impact NVIDIA’s revenue and earnings growth, while competition from rivals like Advanced Micro Devices, Inc. (AMD - Free Report) continues to increase.  

At the same time, U.S. export curbs on cutting-edge AI chips to China have constrained NVIDIA’s entry to a key market, potentially pressuring its margins. Additionally, NVIDIA remains exposed to supply-chain disruptions due to its dependency on Taiwan Semiconductor Manufacturing Company Limited (TSM - Free Report) for advanced chip production amid ongoing geopolitical tensions. 

Given these challenges, it’s becoming increasingly difficult for NVIDIA to meet sky-high expectations. Thus, investors seeking AI exposure should look for much smaller companies with greater room for expansion. Notable among them are Western Digital Corporation (WDC - Free Report) and Seagate Technology Holdings plc (STX - Free Report) , whose shares have soared 662.8% and 464.5%, respectively, over the past year, outpacing NVIDIA’s gain of 22.6%. 

Both Western Digital and Seagate stand to gain from the rapid growth in AI-driven demand for data storage. Let’s take a closer look at the key catalysts that could drive further upside in these AI stocks –  

Western Digital’s AI Storage Boom Could Drive Further Upside Rising demand for high-value enterprise hard disk drives and a favorable pricing environment have created a solid growth runway for Western Digital. The company’s revenues totaled $3.34 billion in the fiscal third quarter of 2026, up 45% year over year, according to the company’s press release.

Furthermore, the company expects revenues for the fiscal fourth quarter of 2026 to be about $3.65 billion, plus or minus $100 million. The upbeat guidance reflects robust demand for AI infrastructure, with cloud providers and enterprise customers continuing to invest in high-capacity storage to meet increasing AI workloads. 

In the fiscal third quarter, Western Digital’s non-GAAP gross margin rose to 50.5% from 40.1% in the prior-year period. The company projects further margin expansion, with fiscal fourth-quarter non-GAAP gross margin expected to reach 51-52%. The improving gross margin is providing Western Digital with greater financial flexibility to invest in research and development, enhance earnings growth and create long-term value for shareholders. 

As a result, the company’s expected earnings growth rate for the current year is 104.1%. The Zacks Consensus Estimate of $10.06 for WDC’s earnings per share (EPS) is up 54.8% year over year.

 

Image Source: Zacks Investment Research

Seagate’s AI Infrastructure Play Gains Momentum Amid Rising Demand Seagate is well-positioned to sustain its growth momentum, banking on rising data-center storage demand, expanding margins, and robust cash flows. These favorable trends could provide the required upside for Seagate’s shares, strengthening its position as a potential beneficiary of the AI infrastructure boom. 

For the fiscal fourth quarter of 2026, Seagate expects revenues of around $3.45 billion, plus or minus $100 million, more than the $3.11 billion reported in the fiscal third quarter of 2026, according to investors.seagate.com.   

Moreover, a non-GAAP gross margin of 47% in the fiscal third quarter reflected improved operational execution and enhanced profitability. Additionally, the company’s free cash flow of $953 million in the fiscal third quarter showcased the strength in its core business.  

Supported by these trends, Seagate’s expected earnings growth rate for the current year stands at 84.3%, while the Zacks Consensus Estimate of $14.93 for STX’s EPS represents a 47.5% increase from the prior-year period.

 

Image Source: Zacks Investment Research

Both Western Digital and Seagate currently have a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks Rank #1 stocks here.

Rocket Lab (RKLB 11.62%) may excel at soaring into the final frontier, but gravity is weighing pretty heavily on shares today. An analyst initiated coverage on the launch services stock with an unenthusiastic outlook, and investors are choosing to click the sell button as a result.

As of 2:14 p.m. ET, shares of Rocket Lab are down 12.1%.

Image source: Getty Images.

One analyst thinks shares are pricey Assigning a neutral rating, Piper Sandler analyst Alexander Potter initiated coverage on Rocket Lab stock this morning and set an $83 price target. Based on shares of Rocket Lab closing at $76.20 yesterday, Potter's price target implies upside of 8.9%.

Today's Change

(

-11.62

%) $

-8.86

Current Price

$

67.35

According to Thefly.com, Piper Sandler sees Rocket Lab trading at a premium to SpaceX and expects its stock to trade at a similar valuation over the next year. Furthermore, with respect to space stocks, the firm has taken a more bullish view on AST SpaceMobile, initiating coverage after the market closed yesterday with a $100 price target -- representing upside of about 51% from yesterday's closing price of $66.31.

Are investors better off choosing not to lift off with a Rocket Lab investment now? While today's drop in Rocket Lab stock may be disappointing, current investors shouldn't feel compelled to exit their positions based on Piper Sandler's lackluster outlook. It's important to remember that this is merely one firm's opinion, and others see things differently, believing Rocket Lab stock will rise considerably higher through 2026 and beyond.

Of course, analysts' perspectives are one thing, but the most important thing for investors to bear in mind is that it's encumbent on them to exercise their due diligence to see if a Rocket Lab investment is right for them.

Scott Levine has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AST SpaceMobile and Rocket Lab. The Motley Fool has a disclosure policy.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Few things ruin a Saturday morning faster than the words “your timing chain is going.” Car repair bills arrive unannounced, cost more than expected, and have a way of landing the same week as property taxes or insurance renewals. The fix is a small, dedicated slice of capital whose only job is to absorb those bills without forcing a portfolio sale.

The Number You Are Trying to Replace AAA’s 2025 Your Driving Costs study pegs routine maintenance at $792 per year, or $66 per month, for a typical new vehicle. Older cars can cost considerably more once tires, brakes, batteries, and check-engine repairs enter the cycle. For this exercise, $1,500 a year is a reasonable planning target, but the right number should come from your own repair history. And if you’re driving a rusted-out 2005 Lincoln Grand Marquis with 281,000 miles on it, triple that budget… and start a car replacement fund immediately.

Inflation matters. CPI-U rose from 321.465 in June 2025 to 335.123 in May 2026, and motor vehicle maintenance and repair costs were up 6.1% over the year. A static $1,500 income stream loses ground when repair labor and parts keep getting more expensive. The portfolio has to grow.

Tier One: The Sleep-Well Build (3% to 4% Yield) At a 3.5% blended yield, $1,500 divided by 0.035 equals roughly $42,857 of capital. This tier is dividend-growth territory: broad consumer staples, healthcare giants, regulated utilities.

Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) yields 2.1% today but has raised its payout for 64 consecutive years, most recently to $1.34 a quarter. Procter & Gamble (NYSE:PG) yields 2.9% and just hiked its quarterly dividend to $1.0885, extending a streak back seven decades. NextEra Energy yields 2.7% but has compounded its dividend at roughly 10% a year since 2022.

Individual yields sit below 3%, so a real Tier One portfolio blends these names with higher-payout dividend-aristocrat funds to land in the 3% to 4% range. You tie up more capital upfront, but income tends to outpace inflation and shares appreciate.

Tier Two: The REIT-Heavy Middle (5% to 7% Yield) At 6%, the math drops to $25,000. Net-lease and industrial REITs anchor this range alongside preferred shares and high-dividend equity funds.

Realty Income (NYSE:O) yields 5.2%, pays monthly, and has now declared 670 consecutive monthly dividends. Agree Realty (NYSE:ADC) yields 4.1% after raising its monthly payout to $0.267 earlier this year. STAG Industrial yields 3.9% and leases warehouses to single tenants across the country.

Combine a net-lease REIT, an industrial REIT, and a preferred-share ETF and a 6% blended yield is realistic. REIT dividends grow more slowly than a consumer staple’s, and rate volatility can erode principal. The 10-year Treasury at 4.4% sets the bar these names must clear.

Tier Three: The Capital-Light Stretch (8% to 12% Yield) At 11%, you need only about $13,636 to cover $1,500 of repairs. That is genuinely small money, which is why the temptation is real.

This tier lives in business development companies, mortgage REITs, leveraged covered-call ETFs, and high-yield bond funds. The catch is principal erosion. Many high-yield vehicles distribute capital as well as income, so share price drifts lower while the payout stays flat or gets cut. You are spending the asset itself while the payout stays flat.

The Trap Hidden in the Highest Yield The aggressive tier looks cheapest until you account for time. P&G now pays $1.0885 a quarter, up from $0.285 in 1999. NextEra raised its quarterly dividend to $0.6232 in 2026, consistent with its plan for about 10% annual dividend growth through 2026 off a 2024 base. A 3.5% yield that compounds 8% annually doubles its income in about nine years. An 11% yield that never grows stays at $1,500 while repair costs keep climbing.

For a recurring, inflation-linked expense like car repairs, the lower-yield tier can win over a 20-year horizon if the dividends keep growing and the principal compounds. It demands more starting capital, but it also gives the income stream a better chance to keep pace with rising repair costs.

Size the Portfolio Before the Next Breakdown Pull three years of your own repair receipts and set a real target. Drivers of older, luxury, or high-mileage vehicles may need more than $1,500 a year, while owners of newer, simpler, or highly reliable cars may need less. Compare the total return of a dividend-growth fund against a high-yield covered-call fund using the same starting dollar and the same time period. Include reinvested dividends, taxes, and any change in principal. The compounding gap is the core argument for Tier One.

Hold the repair portfolio in the right account for the income it produces. Qualified dividends from many dividend-growth stocks may receive lower federal tax rates when IRS holding-period rules are met. REIT and BDC distributions are often largely ordinary income, though the final tax character can vary by year. That difference can raise the effective capital you need in a taxable account. The goal is to make sure that in 2046, when a transmission goes, the money is already there and the principal is still working. A repair fund is not just a pile of cash waiting for bad news. Built carefully, it is a small income engine that turns one of the most annoying household expenses into a bill the portfolio is already prepared to pay.

Contact [email protected] for any questions or corrections.

July 16, 2026 16:05 ET  | Source: iRhythm

SAN FRANCISCO, July 16, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced that it will release financial results for the second quarter 2026 after the close of trading on Thursday, August 6, 2026. The company’s management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Interested parties may access a live and archived webcast of the conference call on the “Quarterly Results” section of the company’s investor website at investors.irhythmtech.com.

About iRhythm Holdings, Inc.
iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.

Investor Contact
[email protected]

Media Contact
Kassandra Perry
[email protected]

Key Takeaways W.R. Berkley is expected to report Q2 revenue growth of 1.7% and EPS growth of 3.8%.Premium growth and higher investment income may offset higher catastrophe losses.WRB's disciplined underwriting, expense control and share buybacks are expected to aid profitability. W.R. Berkley Corporation (WRB - Free Report) is expected to register an improvement in both top and bottom lines when it reports second-quarter 2026 results on July 20, after market close.

The Zacks Consensus Estimate for WRB’s second-quarter revenues is pegged at $3.7 billion, indicating 1.7% growth from the year-ago reported figure.

The consensus estimate for earnings is pegged at $1.09 per share. The Zacks Consensus Estimate for WRB’s second-quarter earnings has remained unchanged over the past 30 days. The estimate suggests a year-over-year increase of 3.8%.

What the Zacks Model Unveils About WRBOur proven model predict an earnings beat for W.R. Berkley this time around. A stock needs to have the right combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold). This is not the case, as you can see below:

Earnings ESP: W.R. Berkley has an Earnings ESP of +1.84%. This is because the Most Accurate Estimate of $1.11 is pegged higher than the Zacks Consensus Estimate of $1.09. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.

W.R. Berkley Corporation Price and EPS Surprise

W.R. Berkley Corporation price-eps-surprise | W.R. Berkley Corporation Quote

Zacks Rank: W.R. Berkley currently has a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks #1 Rank stocks here.

Factors Likely to Shape Q2 Results of WRBGross premiums written in the Insurance segment are likely to have been supported by healthy momentum in other liability, short-tail lines, professional liability, workers' compensation and commercial auto. We expect the metric to be $3.6 billion, indicating an increase of 1.8% from the year-ago reported number.

The Reinsurance & Monoline Excess segment's gross premiums written are expected to have improved modestly, supported by selective underwriting, although increased competition in the property reinsurance market is likely to have tempered growth. We expect the metric to be $375 million, suggesting an improvement of 1.1% from the year-ago reported number.  

The Zacks Consensus Estimate for second-quarter 2026 premiums earned is pegged at $3.16 billion, indicating an increase of 1.9% from the year-ago reported quarter. Our estimate for the metric is pegged at $3.12 billion, indicating a 0.7% upside from the year-ago reported number.

The increase in income from fixed-maturity securities, investment funds, arbitrage trading accounts, real estate and equity securities is likely to have aided net investment income. Strong operating cash flows and higher reinvestment yields are expected to have further supported investment income growth. The Zacks Consensus Estimate for second-quarter 2026 net investment income is pegged at $395 million, indicating an increase of 4.3% from the year-ago reported quarter.Our estimate for the metric is pegged at $407 million, indicating a 7.3% upside from the year-ago reported number.

Higher losses and loss expenses, other operating costs and expenses, and expenses from non-insurance businesses are likely to increase costs. We expect total expenses to increased 1.7% to $3.2 billion.

Higher net premiums earned and continued expense discipline are expected to have supported the expense ratio, which management expects to remain comfortably below 30% in 2026. We estimate the metric to be 28.30 in the to-be-reported quarter.

The combined ratio is expected to have remained favorable, supported by disciplined underwriting and healthy pricing in casualty lines. However, the second quarter likely experienced elevated severe convective storm , which is likely to have increased catastrophe losses, partially offsetting these benefits. The Zacks Consensus Estimate is pinned at 92, while our estimate for the combined ratio is pegged at 93.39.

Continued share buybacks are likely to have provided additional support to the bottom line.

Stocks to ConsiderHere are three P&C insurance stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat:

Cincinnati Financial Corporation (CINF - Free Report) has an Earnings ESP of +8.84% and a Zacks Rank #2 at present. The Zacks Consensus Estimate for second-quarter 2026 earnings is pegged at $1.77, indicating a year-over-year decrease of 10.1%.

CINF’s earnings beat estimates in each of the last four reported quarters.

Chubb Limited (CB - Free Report) has an Earnings ESP of +1.09% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for second-quarter 2026 earnings is pegged at $6.60, indicating a year-over-year increase of 7.4%.

CB’s earnings beat estimates in each of the last four reported quarters.

The Allstate Corporation (ALL - Free Report) has an Earnings ESP of +23.32% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for second-quarter 2026 earnings is pegged at $4.92, indicating a year-over-year decrease of 17.1%.

ALL’s earnings beat estimates in each of the last four reported quarters.

Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- Tripadvisor, Inc. (NASDAQ: TRIP) announced today that at 7:05am ET on Thursday, August 6, 2026, the company will post its second quarter 2026 financial results on its investor relations website at ir.tripadvisor.com.

The same day, at 8:30am ET, the company will host a conference call to answer questions regarding its financial results.  The event will be webcast live and can be accessed at ir.tripadvisor.com.  A replay will be available on the website for three months.

About Tripadvisor, Inc.

The Tripadvisor Group connects people to experiences worth sharing, and aims to be the world's most trusted source for travel and experiences. We leverage our brands, technology, and capabilities to connect our global audience with partners through rich content, travel guidance, and two-sided marketplaces for experiences, restaurants, and other travel categories such as hotels. The subsidiaries of Tripadvisor, Inc. (Nasdaq: TRIP), include a portfolio of travel brands and businesses, including Tripadvisor, Viator, and TheFork.

TRIP-G

SOURCE Tripadvisor

Also from this source